Personal Introduction:

Yu He Scholar; Distinguished Professor

Senior Investigator & Associate Director, Shanghai Institute of Immunology,

Adjunct “Guangci” Professor, Shanghai Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Jiao Tong University

Education:

1996.09-2001.07 Doctor candidate, College of Life Sciences, Peking University

1992.09-1996.07 Bachelor candidate, Dept of Biology, Anhui Normal University

Career:

2016.09-current Senior Investigator, Shanghai Institute of Immunology, SJTUSM

2009.02-2016.09 Principle Investigator, Institut Pasteur of Shanghai, CAS

2006.07-2009.02 Faculty Research Associate, University of Pennsylvania School of Medicine

2002.10-2003.07   Visiting Research Scholar, Oxford University Dunn School of Pathology

2001.09-2006.07 Postdoctoral Fellow, University of Pennsylvania School of Medicine

Scientific Research Projects:

• National Natural Science Foundation of China (Special Program), Screening FOXP3 inhibitors for antitumor immunotherapy, Ongoing

• National Natural Science Foundation of China (Key Program), Systematic identification of adipose tissue regulatory T-cell subsets and their physiological functions, Ongoing

• Ministry of Science and Technology of China (National Science and Technology Major Project), Identification of new targets for immunotherapy-resistant colorectal cancer subtypes and development of immune-sensitizing drugs, Ongoing

• National Natural Science Foundation of China (Special Program), Dynamic evolution of immune responses before and after liver transplantation and its regulatory mechanisms (Joint Application B), Completed

• Ministry of Science and Technology of China (Key R&D Program), Construction and functional study of engineered CAR-T cells resistant to Treg-mediated suppression, Completed

• National Natural Science Foundation of China (Mid-scale International Cooperation Program), Novel strategies targeting Th17/Treg immune balance for cancer immunotherapy, Completed

• National Natural Science Foundation of China (Key Program), Novel strategies targeting Th17/Treg immune balance in autoimmune diseases, Completed

• National Natural Science Foundation of China (Distinguished Young Scholars Program), Completed

• National Natural Science Foundation of China (Key Program), Dynamic effects of inflammatory cytokines on FOXP3⁺ regulatory T-cell differentiation and function and the underlying mechanisms, Completed

Publications:

1. Wang, Jin; Zhao, Wenying; Bai, Wenjuan; Dong, Dong; Wang, Hui; Qi, Xin; Thanabalasuriar, Ajitha; Ye, Youqiong; Xu, Tian-le; Li, Hecheng; Kubes, Paul; Li, Bin; Wang, Jing; PIEZO1 mediates mechanical reprogramming of neutrophils for proangiogenic specialization in the lung, Journal of Clinical Investigation, 2025, 135(11)

2. Jiang, Zhenyan; Wang, Huizi; Wang, Xiaoxia; Duo, Hongrui; Tao, Yuexiao; Li, Jia; Li, Xin; Liu, Jiamin; Ni, Jun; Wu, Emily Jiatong; Xiang, Hongrui; Guan, Chenyang; Wang, Xinyu; Zhang, Kun; Zhang, Peng; Hou, Zhaoyuan; Liu, Yong; Wang, Zhengting; Su, Bing; Li, Bo; Hao, Youjin; Li, Bin; Wu, Xuefeng; TMED4 facilitates regulatory T cell suppressive function via ROS homeostasis in tumor and autoimmune mouse models, Journal of Clinical Investigation, 2025, 135(1)

3. Huang Qianru; Tian Na; Zhang Jianfeng; Song Shiyang; Cheng Hao; Liu Xinnan; Zhang Wenle; Ye Youqiong; Du Yanhua; Dai Xueyu; Liang Rui; Li Dan; Dai Shengming; Wang Chuan; Chen Zhi; Zhou Qianjun; Li Bin; Non-classical action of Ku70 promotes Treg suppressive function through a FOXP3-dependent mechanism in lung adenocarcinoma, Journal of Clinical Investigation, 2024, 134(23)

4. Xu, Nannan; Zhu, Yemin; Han, Yichao; Liu, Qi; Tong, Lingfeng; Li, Yakui; Chen, Zhangbing; Shao, Sijia; He, Wenrui; Li, Mingrui; Wang, Yi; Qiang, Siyuan; Chai, Peiwei; Du, Peng; Zhao, Wenyi; Wu, Lifang; Zhang, Ping; He, Jianli; Li, Hecheng; Cheng, Jinke; Jia, Renbing; Li, Bin; Lu, Ying; Tong, Xuemei; Targeting MondoA-TXNIP restores antitumour immunity in lactic-acid-induced immunosuppressive microenvironment, Nature Metabolism, 2025, Sep;7(9): 1889-1904

5. Liu Xinnan; Zhang Weiqi; Han Yichao; Cheng Hao; Liu Qi; Ke Shouyu; Zhu Fangming; Lu Ying; Dai Xin; Wang Chuan; Huang Gonghua; Su Bing; Zou Qiang; Li Huabing; Zhao Wenyi; Xiao Lianbo; Lu Linrong; Tong Xuemei; Pan Fan; Li Hecheng; Li Bin; FOXP3+ regulatory T cell perturbation mediated by the IFNγ-STAT1-IFITM3 feedback loop is essential for anti-tumor immunity, Nature Communications, 2024, 15(1)

6. Tian, Na; Cheng, Hao; Du, Yu; Wang, Xiaoxia; Lei, Yi; Liu, Xinnan; Chen, Miao; Xu, Zhan; Wang, Lingbiao; Yin, Hanlin; Fu, Rong; Li, Dan; Zhou, Penghui; Lu, Liangjing; Yin, Zhinan; Dai, Sheng-Ming; Li, Bin; Cannabinoid receptor 2 selective agonist alleviates systemic sclerosis by inhibiting Th2 differentiation through JAK/SOCS3 signaling, JOURNAL OF AUTOIMMUNITY, 2024, 147(103233)

7. Hanlin Yin; Oliver Distler; Lichong Shen; Xiaojiang Xu; Ye Yuan; Rui Li; Bei Liu; Qianqian Li; Qianru Huang; Feng Xie; Zhiliang Zhang; Rui Liang; Xueyu Dai; Xiaoxiang Chen; Bin Li; Qingran Yan; Liangjing Lu; Endothelial Response to Type I Interferon Contributes to Vasculopathy and Fibrosis and Predicts Disease Progression of Systemic Sclerosis, Arthritis Rheumatology, 2023, 76(1): 78-91

8. Liu, Qi; Zhu, Fangming; Liu, Xinnan; Lu, Ying; Yao, Ke; Tian, Na; Tong, Lingfeng; David A. Figge; Wang, Xiuwen; Han, Yichao; Li, Yakui; Zhu, Yemin; Hu, Lei; Ji, Yingning; Xu, Nannan; Li, Dan; Gu, Xiaochuan; Liang, Rui; Gan,Guifang; Wu, Lifang; Zhang, Ping; Xu, Tianle; Hu, Hui; Hu, Zeping; Xu, Huji; Ye, Dan; Yang, Hui; Li, Bin; Tong, Xuemei; Non-oxidative pentose phosphate pathway controls regulatory T cell function by integrating metabolism and epigenetics, Nature Metabolism, 2022, 4(5): 559-574

9. Deng, Biaolong; Yang, Biaolong; Chen, Jieqiong; Wang, Shuaiwei; Zhang, Weiqi; Guo, Yixian; Han, Yichao; Li, Hecheng; Dang, Yongjun; Yuan, Yaqin; Dai, Xueyu; Zang, Yuansheng; Li, Yangyang; Li, Bin; Gallic acid induces T-helper-1-like Treg cells and strengthens immune checkpoint blockade efficacy, Journal for ImmunoTherapy of Cancer, 2022, 10(7)

10. Xu, Heng; Zhu, Zhu; Hu, Jian; Sun, Jiawei; Wo, Yan; Wang, Dian; Zou, Hongzhi; Li, Bin; Zhang, Yixin; Downregulated cytotoxic CD8+ T-cell identifies with the NKG2A-soluble HLA-E axis as a predictive biomarker and potential therapeutic target in keloids, Cellular & Molecular Immunology, 2022, 19(4): 527-539

11. Zheng Jian; Yichao Han; Wentian Zhang; Chengqiang Li; Wei Guo; Xijia Feng; Bin Li; Hecheng Li; Anti-tumor effects of dual PI3K-HDAC inhibitor CUDC-907 on activation of ROS-IRE1α- JNK-mediated cytotoxic autophagy in esophageal cancer, Cell & Bioscience, 2022, 12(1)

12. Li, Yangyang; Lu, Ying; Lin, Shu-Hai; Li, Ning; Han, Yichao; Huang, Qianru; Zhao, Yi; Xie, Feng; Guo, Yixian; Deng, Biaolong; Tsun, Andy; Du, Juan; Li, Dan; Sun, Joanne; Shi, Guochao; Zheng, Fang; Su, Xiao; Duan, Shengzhong; Zheng, Song Guo; Wang, Gang; Tong, Xuemei; Li, Bin; Insulin signaling establishes a developmental trajectory of adipose regulatory T cells, Nature Immunology, 2021, 22(9): 1175-1185

13. Liu, Yahui; Du, Juan; Liu, Xinnan; Wang, Lingbiao; Han, Yichao; Huang, Chunrong; Liang, Rui; Zheng, Fang; Shi, Guochao; Li, Bin; MG149 inhibits histone acetyltransferase KAT8-mediated IL-33 acetylation to alleviate allergic airway inflammation and airway hyperresponsiveness, Signal Transduction and Targeted Therapy, 2021, 6(1)

14. Lu, Ying; Li, Yangyang; Liu, Qi; Tian, Na; Du, Peng; Zhu, Fangming; Han, Yichao; Liu, Xinnan; Liu, Xisheng; Peng, Xiao; Wang, Xiaoxia; Wu, Yuchen; Tong, Lingfeng; Li, Yakui; Zhu, Yemin; Wu, Lifang; Zhang, Ping; Xu, Ye; Chen, Hanbei; Li, Bin; Tong, Xuemei; MondoA-Thioredoxin-Interacting Protein Axis Maintains Regulatory T-Cell Identity and Function in Colorectal Cancer Microenvironment, Gastroenterology, 2021, 161(2): 575-591

15. Zhai, Tianhang; Wang, Chao; Xu, Yifeng; Huang, Weifeng; Yuan, Zhijun; Wang, Tao; Dai, Shuang; Peng, Shaogang; Pang, Tuling; Jiang, Wenchao; Huang, Yuhua; Zou, Yuefeng; Xu, Yingda; Sun, Joanne; Gong, Xinjiang; Zhang, Jinping; Tsun, Andy; Li, Bin; Miao, Xiaoniu; Generation of a safe and efficacious llama single-domain antibody fragment (vHH) targeting the membrane-proximal region of 4-1BB for engineering therapeutic bispecific antibodies for cancer, Journal for ImmunoTherapy of Cancer, 2021, 9(6)

16. Li, Yangyang; Lu, Yue; Wang, Shuaiwei; Han, Zhijun; Zhu, Fuxiang; Ni, Yingmeng; Liang, Rui; Zhang, Yan; Leng, Qibin; Wei, Gang; Shi, Guochao; Zhu, Ruihong; Li, Dan; Wang, Haikun; Zheng, Song Guo; Xu, Hongxi; Tsun, Andy; Li, Bin; USP21 prevents the generation of T-helper-1-like Treg cells, Nature Communications, 2016, 7: 13559

17. Chen, Zuojia; Barbi, Joseph; Bu, Shurui; Yang, Huang-Yu; Li, Zhiyuan; Gao, Yayi; Jinasena, Dilini; Fu, Juan; Lin, Fang; Chen, Chen; Zhang, Jing; Yu, Ning; Li, Xiangpei; Shan, Zhao; Nie, Jia; Gao, Zhimei; Tian, Hong; Li, Yangyang; Yao, Zhengju; Zheng, Ying; Park, Benjamin V; Pan, Ziyi; Zhang, Jing; Dang, Eric; Li, Zhiguang; Wang, Honglin; Luo, Weibo; Li, Liwu; Semenza, Gregg L; Zheng, Song-Guo; Loser, Karin; Tsun, Andy; Greene, Mark I; Pardoll, Drew M; Pan, Fan; Li, Bin; The ubiquitin ligase Stub1 negatively modulates regulatory T cell suppressive activity by promoting degradation of the transcription factor Foxp3, Immunity, 2013, 39(2): 272-285

Patent:

• Li Bin; Tian Na; Cheng Hao; Liang Rui; Li Dan; Dai Sheng-Ming; Application of a CB2 receptor–specific agonist in the preparation of a medicament for the treatment of atopic dermatitis, 2024-03-29, China, 202410376959.9

• Li Bin; Wang Xiaoxia; Cheng Hao; Tian Na; Liang Rui; Application of an IRE1α inhibitor in the preparation of a medicament for the treatment of multiple sclerosis, 2023-09-07, China, CN202311152132.1

• Li Bin; Li Yangyang; Deng Biaolong; Liang Rui; Li Dan; Dai Xueyu; Application of gallic acid in the treatment of colorectal cancer and in promoting Anti-PD-1–mediated antitumor effects, 2022-04-05, China, 2022103524501